These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 1601753)
1. The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus. Seibert G; Isert D; Klesel N; Limbert M; Markus A; Schrinner E J Antimicrob Chemother; 1992 Apr; 29 Suppl A():25-30. PubMed ID: 1601753 [TBL] [Abstract][Full Text] [Related]
2. In-vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase-negative staphylococci. Raymond J; Vedel G; Bergeret M J Antimicrob Chemother; 1996 Dec; 38(6):1067-71. PubMed ID: 9023655 [TBL] [Abstract][Full Text] [Related]
3. In-vitro bactericidal activity of cefpirome and cefamandole in combination with glycopeptides against methicillin-resistant Staphylococcus aureus. Bergeret M; Raymond J J Antimicrob Chemother; 1999 Feb; 43(2):291-4. PubMed ID: 11252338 [TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo activity of cefpirome (HR 810) against methicillin-susceptible and -resistant Staphylococcus aureus and Streptococcus faecalis. Eng RH; Cherubin CE; Smith SM; Buccini F; Harris R J Antimicrob Chemother; 1989 Mar; 23(3):373-81. PubMed ID: 2499565 [TBL] [Abstract][Full Text] [Related]
5. TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus. Hanaki H; Akagi H; Masaru Y; Otani T; Hyodo A; Hiramatsu K Antimicrob Agents Chemother; 1995 May; 39(5):1120-6. PubMed ID: 7625799 [TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus. Goldstein EJ; Citron DM Antimicrob Agents Chemother; 1985 Jul; 28(1):160-2. PubMed ID: 3929677 [TBL] [Abstract][Full Text] [Related]
7. [Evaluation of the activity and effects of combinations of various antibacterial agents against methicillin-resistant Staphylococcus aureus in vitro]. Kouda M; Homma S; Udagawa I; Fukuhara J; Takeuchi M; Tamura K Jpn J Antibiot; 2000 Mar; 53(3):171-8. PubMed ID: 10834148 [TBL] [Abstract][Full Text] [Related]
8. CP6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Ida T; Tsushima M; Ishii T; Atsumi K; Tamura A J Infect Chemother; 2002 Jun; 8(2):138-44. PubMed ID: 12111566 [TBL] [Abstract][Full Text] [Related]
9. In vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase-negative Staphylococcus. Raymond J; Vedel G; Bergeret M Diagn Microbiol Infect Dis; 1998 Jul; 31(3):481-3. PubMed ID: 9635241 [No Abstract] [Full Text] [Related]
10. In vitro antibacterial activity of TOC-50, a new parenteral cephalosporin against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Nomura S; Hanaki H; Unemi N Chemotherapy; 1996; 42(4):253-8. PubMed ID: 8804792 [TBL] [Abstract][Full Text] [Related]
11. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Allen GP; Cha R; Rybak MJ Antimicrob Agents Chemother; 2002 Aug; 46(8):2606-12. PubMed ID: 12121940 [TBL] [Abstract][Full Text] [Related]
12. Synergistic enhancement of in vitro antimicrobial activity of imipenem and cefazolin, cephalothin, cefotiam, cefamandole or cefoperazone in combination against methicillin-sensitive and -resistant Staphylococcus aureus. Uete T; Matsuo K Jpn J Antibiot; 1995 Mar; 48(3):402-8. PubMed ID: 7752453 [TBL] [Abstract][Full Text] [Related]
13. In vitro synergy between cefepime and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis. Lozniewski A; Lion C; Mory F; Weber M J Antimicrob Chemother; 2001 Jan; 47(1):83-6. PubMed ID: 11152435 [TBL] [Abstract][Full Text] [Related]
14. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975 [TBL] [Abstract][Full Text] [Related]
15. In-vitro evaluation of cefpirome (HR 810), teicoplanin and four other antimicrobials against enterococci. Chandrasekar PH; Price S; Levine DP J Antimicrob Chemother; 1985 Aug; 16(2):179-82. PubMed ID: 2933380 [TBL] [Abstract][Full Text] [Related]
16. [Combination effect of vancomycin and cefpirome against methicillin-resistant Staphylococcus aureus in vitro--antimicrobial activities in postantibiotic phase]. Hasegawa H; Kanai A; Otoguro K; Shimizu K Kansenshogaku Zasshi; 1996 Feb; 70(2):151-60. PubMed ID: 8851387 [TBL] [Abstract][Full Text] [Related]
17. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Brumfitt W; Salton MR; Hamilton-Miller JM J Antimicrob Chemother; 2002 Nov; 50(5):731-4. PubMed ID: 12407132 [TBL] [Abstract][Full Text] [Related]
18. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Deshpande LM; Jones RN Clin Microbiol Infect; 2003 Nov; 9(11):1120-4. PubMed ID: 14616730 [TBL] [Abstract][Full Text] [Related]
19. In vitro antibacterial activities of FK037: a new parenteral cephalosporin. Inoue K; Inoue E; Mitsuhashi S Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206 [TBL] [Abstract][Full Text] [Related]
20. Novel semi-synthetic glycopeptide antibiotics active against methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE): doubly-modified water-soluble derivatives of chloroorienticin B. Yoshida O; Yasukata T; Sumino Y; Munekage T; Narukawa Y; Nishitani Y Bioorg Med Chem Lett; 2002 Nov; 12(21):3027-31. PubMed ID: 12372494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]